When researchers expressed frustration that the
existing CTLA-4 antibodies on the market weren’t
producing reliable IHC results, CST went to work and
developed a high-performing option. As a company
founded and led by active scientists, we understand
the importance of having products you can count on.
We validate every one of our thousands of antibodies
and research products in-house—and in multiple
applications where indicated. If any product fails
to meet our stringent standards, we keep refining it
until it does. Scientists all over the world trust CST®
products towork—first time, every time. You can, too.© 2022 Cell Signaling Technology, Inc. Cell Signaling Technology, CST, and XP are trademarks or registered trademarks of Cell Signaling Technology, Inc. 22-BCH-37353-MAYOURPROCESS—YOURSUCCESS.
Immune checkpoint inhibition, especially in combination with other therapeutic agents, has shown
promise in the treatment of a variety of cancers. To successfully develop such therapies, researchers
must have reliable tools to detect the checkpoint proteins and ligands in tissue, in addition to other
therapeutic readouts. Shown here is paraffin-embedded human B-cell non-Hodgkin lymphoma stained
for the immune checkpoint protein CTLA-4, using CTLA-4 (E2V1Z) Rabbit mAb #53560.THE ROAD TO SUCCESS
IS PAVED WITH FAILURE.
UNTIL IT’S NOT.
0506Product.indd 548 4/28/22 8:18 AM